![All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1613cdc1-b321-464f-b17b-ec4249d7b88e/gr1_lrg.jpg)
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer
OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
![Inflammation and tumor progression: signaling pathways and targeted intervention | Signal Transduction and Targeted Therapy Inflammation and tumor progression: signaling pathways and targeted intervention | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-021-00658-5/MediaObjects/41392_2021_658_Fig1_HTML.png)
Inflammation and tumor progression: signaling pathways and targeted intervention | Signal Transduction and Targeted Therapy
![Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML](https://www.mdpi.com/biomolecules/biomolecules-10-01387/article_deploy/html/images/biomolecules-10-01387-g001.png)
Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML
![US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents](https://patentimages.storage.googleapis.com/57/01/9c/e44c8fb83ae3ed/US20170137528A1-20170518-D00007.png)
US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d0668b16-6f13-4a1b-99c6-7416a2f7b1b3/ctm2346-fig-0002-m.jpg)